C4 Therapeutics, Inc.CCCCNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-0.79%
↓ 117% below average
Average (26q)
4.76%
Historical baseline
Range
High:34.77%
Low:-25.86%
Volatility
1274.8%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -0.79% |
| Q2 2025 | -3.23% |
| Q1 2025 | -16.73% |
| Q4 2024 | 2.12% |
| Q3 2024 | 34.04% |
| Q2 2024 | 5.41% |
| Q1 2024 | -25.86% |
| Q4 2023 | 7.21% |
| Q3 2023 | -5.28% |
| Q2 2023 | 3.04% |
| Q1 2023 | -5.25% |
| Q4 2022 | 3.33% |
| Q3 2022 | -5.30% |
| Q2 2022 | 19.54% |
| Q1 2022 | -1.31% |
| Q4 2021 | 9.25% |
| Q3 2021 | 4.36% |
| Q2 2021 | 13.45% |
| Q1 2021 | 0.46% |
| Q4 2020 | -14.63% |
| Q3 2020 | 34.77% |
| Q2 2020 | 8.88% |
| Q1 2020 | 1.84% |
| Q4 2019 | 27.86% |
| Q3 2019 | 0.00% |
| Q2 2019 | 31.22% |
| Q1 2019 | 0.00% |